Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Navigating discussions with patients who have high-risk genomics but are reluctant about chemo

Inimfon Jackson • 30 May 2025
ASCO 2025
Breast Cancer General

Inimfon Jackson, MD, PhD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX, provides guidance on navigating discussions with patients who have high-risk genomic profiles but express reluctance towards chemotherapy. Dr Jackson emphasizes the need to be well-equipped with data and to understand the patient’s perspective, presenting the benefits and risks of treatment options in a clear and unbiased manner. This approach enables patients to make informed decisions about their care. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Inimfon Jackson

Addressing access barriers and guideline-concordant breast cancer care
1:07
Addressing access barriers and guideline-concordant breast cancer care
Inimfon Jackson • 10 Dec 2025
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
2:28
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
Inimfon Jackson • 10 Dec 2025
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
1:53
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
Inimfon Jackson • 30 May 2025
Addressing disparities in chemotherapy acceptance: barriers and potential solutions
1:21
Addressing disparities in chemotherapy acceptance: barriers and potential solutions
Inimfon Jackson • 30 May 2025

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
Educational impact of a guideline-based hematology-oncology bootcamp curriculum
2:41
Educational impact of a guideline-based hematology-oncology bootcamp curriculum
Chinmay Jani • 31 May 2026
The content of VJOncology is intended for healthcare professionals